Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 21 Mar 2023
At a glance
- Drugs Insulin efsitora alfa (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 20 Mar 2023 Results (From two studies n=73,NCT02942914 and n=33,NCT03367377) assessing safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of basal insulin Fc (BIF; LY3209590) in development for once-weekly dosing for the treatment of patients with diabetes published in the Diabetes, Obesity and Metabolism
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.